ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
Portfolio Pulse from
ZIVO Bioscience, Inc. has reported promising preliminary results from a study on its proprietary active ingredients' efficacy in reducing the transmission of Low Pathogenicity Avian Influenza (LPAI) virus. The study was conducted in collaboration with the University of Delaware.
December 20, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ZIVO Bioscience has announced favorable preliminary results from a study on its proprietary active ingredients' ability to reduce Avian Influenza transmission. This could enhance ZIVO's market position and investor interest.
The positive preliminary results from the study suggest that ZIVO's proprietary ingredients could be effective in combating Avian Influenza, potentially leading to increased demand for their products. This news is likely to boost investor confidence and positively impact ZIVO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100